Hereditary Sensory and Autonomic Neuropathy Type 2
Symptoms, Doctors, Treatments, Advances & More

Hereditary Sensory and Autonomic Neuropathy Type 2 Overview

Save information for later
Sign Up

Learn About Hereditary Sensory and Autonomic Neuropathy Type 2

What is the definition of Hereditary Sensory and Autonomic Neuropathy Type 2?
A rare hereditary sensory and autonomic neuropathy characterized by profound and universal sensory loss involving large and small fiber nerves.
What are the alternative names for Hereditary Sensory and Autonomic Neuropathy Type 2?
  • Hereditary sensory and autonomic neuropathy type 2
  • Giaccai type acroosteolysis
  • HSAN2
  • Hereditary sensory neuropathy type 2
  • Hereditary sensory radicular neuropathy, recessive form
  • Morvan disease
  • Neurogenic acroosteolysis
  • Neuropathy, congenital sensory
  • Neuropathy, progressive sensory, of children
Who are the top Hereditary Sensory and Autonomic Neuropathy Type 2 Local Doctors?
Elite in Hereditary Sensory and Autonomic Neuropathy Type 2
Dr. Horacio Kaufmann
Neurology
Elite in Hereditary Sensory and Autonomic Neuropathy Type 2
Dr. Horacio Kaufmann
Neurology

Dysautonomia Center LLP

530 1st Ave Ste 9Q, 
New York, NY 
212-263-7225
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Horacio Kaufmann is a Neurologist in New York, New York. Dr. Kaufmann is rated as an Elite provider by MediFind in the treatment of Hereditary Sensory and Autonomic Neuropathy Type 2. His top areas of expertise are Familial Dysautonomia, Hajdu-Cheney Syndrome, Hereditary Sensory and Autonomic Neuropathy Type 2, and Orthostatic Hypotension.

Elite in Hereditary Sensory and Autonomic Neuropathy Type 2
Thorsten Hornemann
Elite in Hereditary Sensory and Autonomic Neuropathy Type 2
Thorsten Hornemann
Zurich, ZH, CH 

Thorsten Hornemann practices in Zurich, Switzerland. Mr. Hornemann is rated as an Elite expert by MediFind in the treatment of Hereditary Sensory and Autonomic Neuropathy Type 2. His top areas of expertise are Hereditary Sensory Neuropathy Type 1 (HSN1), Hereditary Sensory and Autonomic Neuropathy Type 2, Hajdu-Cheney Syndrome, Anhidrosis, and Gastric Bypass.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Hereditary Sensory and Autonomic Neuropathy Type 2
Ingo Kurth
Elite in Hereditary Sensory and Autonomic Neuropathy Type 2
Ingo Kurth
Aachen, NW, DE 

Ingo Kurth practices in Aachen, Germany. Mr. Kurth is rated as an Elite expert by MediFind in the treatment of Hereditary Sensory and Autonomic Neuropathy Type 2. His top areas of expertise are Hajdu-Cheney Syndrome, Hereditary Sensory and Autonomic Neuropathy Type 2, Hereditary Sensory Neuropathy Type 1 (HSN1), Anhidrosis, and Bone Marrow Transplant.

View All Doctors
What are the latest Hereditary Sensory and Autonomic Neuropathy Type 2 Clinical Trials?
A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients With Advanced or Metastatic Solid Tumors
A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients With Advanced or Metastatic Solid Tumors
Who is this study for: Patients with Cancer
Enrollment Status: Recruiting
Publish Date: January 05, 2026
Intervention Type: Drug
Study Drugs: ART0380, Gemcitabine
Study Phase: Phase 1/Phase 2

Summary: This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone and in combination with gemcitabine or irinotecan * Learn more about the side effects of ART0380 alone and in combination with gemcitabine or irinotecan * Learn mo...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase I, Multicenter Study to Assess the Safety, Tolerability, and Pharmacokinetics of Ascending Doses of AZD1390 in Combination With Radiation Therapy in Patients With Glioblastoma Multiforme and Brain Metastases From Solid Tumors
A Phase I, Multicenter Study to Assess the Safety, Tolerability, and Pharmacokinetics of Ascending Doses of AZD1390 in Combination With Radiation Therapy in Patients With Glioblastoma Multiforme and Brain Metastases From Solid Tumors
Who is this study for: Patients with glioblastoma multiforme and brain metastases from solid tumors
Enrollment Status: Recruiting
Publish Date: December 22, 2025
Intervention Type: Radiation, Drug
Study Drug: AZD1390
Study Phase: Phase 1

Summary: This study will test an investigational drug called AZD1390 in combination with radiation therapy for the treatment of brain tumors. This is the first time AZD1390 is being given to patients. This study will test safety, tolerability and PK (how the drug is absorbed, distributed and eliminated) of ascending doses of AZD1390 in combination with distinct regimens of radiation therapy

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center